CTOs on the Move


 
Icagen is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.icagen.com
  • 4222 Emperor Blvd Ste 350
    Durham, NC USA 27703
  • Phone: 919.941.5206

Executives

Name Title Contact Details

Similar Companies

Partner Therapeutics

Partner Therapeutics is devoted to developing and commercializing cancer medicines and combination therapies that can make a meaningful difference in the lives of cancer patients.

OrthoVirginia

OrthoVirginia is the state`s largest provider of expert orthopedic and therapy care which serves the needs of its patients through a team of highly trained specialists who are committed to the independent practice of medicine. Located in Lynchburg, northern Virginia and Richmond, OrthoVirginia has more than 100 physicians, 23 office locations, MRI facilities, outpatient surgery centers and physical therapy clinics. Its mission is to improve the musculoskeletal health and well-being of those who live in the communities that it serves. OrthoVirginia`s statewide network of physicians and healthcare providers strives to deliver high quality, cost effective orthopedic care to its patients.

OpGen

OpGen, Inc. is a leading innovator in rapid, accurate genomic and DNA analysis systems and services.

PAR Management

PAR Management is a Newton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Miragen Therapeutics

miRagen Therapeutics, Inc., is a biopharmaceutical company discovering and developing innovative microRNA (miRNA)-targeting therapies to improve human health, specifically in disease areas of high unmet medical need. The company leverages in-house expertise in miRNA biology, oligonucleotide chemistry, and drug development to evaluate and advance best-in-class technologies and high-potential drug candidates for its own pipeline or in conjunction with strategic partners. From its founding, miRagen has developed ongoing, collaborative relationships with academic institutions that give the company unique access to the most promising early-stage discoveries. This access to groundbreaking science provides a significant strategic advantage in the rapidly-developing field of miRNA-targeting therapeutics.